Financial Shenanigans
The Forensic Verdict
The Magnum Ice Cream Company (TMICC, MICC) is a five-month-old standalone entity carved out of Unilever on 6 December 2025, and almost every unusual line on the FY2025 statements traces back to that mechanic rather than to management intent. We grade the forensic risk as Watch (38/100): the GAAP-versus-adjusted gap is structurally large (€656M of EBITDA "adjusting items" plus another €425M–€450M guided for 2026), related-party balances with Unilever total roughly €1.7 billion, and a US-listed first-year standalone issuer does not move to full SOX 404(b) compliance until FY2026. There is no restatement, no qualified opinion, no auditor change, and management has been explicit about the bridging items — that is what keeps this out of "Elevated". The single piece of evidence that would most change the grade is the FY2026 audit outcome under SOX 404(b) and the unwind of the €905M inventory subsidy / €818M inventory accrual at the end of the Transitional Period.
Forensic Risk Score (0–100)
Red Flags
Yellow Flags
3-Yr CFO / Net Income
FY2025 FCF / Net Income
Read FY2022–FY2024 as carve-out, not standalone. Prior periods reflect cost, depreciation, treasury and working-capital allocations under Unilever ownership. Management states the Group "did not retain cash generated from operating activities" before the demerger. Year-over-year comparisons cross an accounting regime change.
13-Shenanigan Scorecard
Six of the 13 categories carry yellow flags, all linked to a single root cause — a two-year Transitional Period during which Unilever still holds inventory, services back-office, and intermediates working capital. The one red flag is the size and pace of non-IFRS adjustments, which will only fade if the FY2026–FY2027 actuals come in close to the guided €425M–€450M of adjusting items and not above.
Breeding Ground
TMICC's governance scaffolding looks credible for a first-year standalone issuer, but two structural conditions push the breeding-ground risk above neutral: a 19.85% legacy parent stake with continuing operational entanglement, and an Internal-Controls-over-Financial-Reporting regime that is mid-transition. The audit committee is chaired by an experienced ex-Heineken CFO (René Hooft Graafland), the auditor is KPMG (proposed for reappointment through FY2027), and the CEO/CFO are seasoned operators with prior carve-out experience (Bhattacharya led Philips carve-outs for 35+ years). What pulls the score up to "yellow" is the SOX 404 step-change in 2026 and the discretionary 125% strategic-priorities multiplier applied to executive bonuses despite a -48% drop in GAAP net income.
Bonus geometry deserves attention. With a 76% business-performance factor and a 125% strategic-priorities multiplier (the design maximum), the formulaic outcome was 95% of target. The strategic multiplier is documented as discretionary and was used at the cap to reward "successful separation and listing". In a year when GAAP net income fell €288M, the alignment between paid-out incentive and headline shareholder result is not tight.
Earnings Quality
Underlying earnings quality is mixed. Organic sales growth of 4.2% (volume 1.5%, price 2.6%) is consistent with a modestly growing global ice-cream category and is corroborated by per-market detail. The €165M decline in GAAP operating profit from FY24 to FY25 is fully explained by disclosed bridge items — TSA cash charges replacing intra-group depreciation, separation/restructuring, FX translation, Türkiye hyperinflation, and 380bps of commodity inflation. What forces a "yellow" call here is not the income statement itself but the dependence on adjustments to read it: GAAP operating margin compressed from 9.6% to 7.6%, while the adjusted EBIT margin shows a far smaller 50bp decline.
Revenue, receivables, and the demerger spike
The €905M inventory subsidy paid to Unilever is recognised inside trade receivables and is the dominant driver of the headline DSO move from 29 to 83 days. Strip it out and underlying receivables grew from €635M to €885M — still a 39% increase against ~flat revenue, which is explained by indirect tax receivables on asset transfers (€120M long-term portion sits in other non-current assets, with current portion in receivables). Underlying operational DSO is essentially flat per management; we accept that claim because inventory days improved 2 days and payables days held flat, consistent with no working-capital lifeline.
Gross margin and operating margin
The two adjusted-EBITDA datapoints (16.9% → 15.9%) tell a much milder story than the GAAP series. Management's bridge attributes 50bp of the decline to FX translation and 50bp to TSA cash costs replacing previously allocated depreciation. Both are real and disclosed. The risk is that the same items continue to be styled as "transitional" through 2027 even after the run-rate is established.
Capex, depreciation, and the under-allocation question
Capex/D&A flipped from 0.85x in FY24 to 1.06x in FY25, and 4.5% of revenue is in line with management's stated reinvestment cadence. The more interesting point is the D&A pattern: depreciation fell €38M in FY25 because Unilever-allocated D&A for shared assets that did not transfer to TMICC is now charged as a cash TSA fee rather than a non-cash expense. That implies pre-demerger D&A was already a complete charge for assets the Group did not own, but understated the standalone cash cost of running the business — a presentation issue more than a manipulation issue, but it inflates pre-demerger EBITDA versus comparable post-demerger EBITDA.
Cash Flow Quality
Three different FCF numbers were used to describe FY2025 in the same week of earnings releases, and the gap between them is the single most important forensic point in this section. The headline FY2025 FCF is €38M (MD&A and CFO commentary). The arithmetic FCF from the cash-flow statement (operating CF €483M minus capex €357M) is €126M. The "comparable FCF excluding separation" presented in the bridge is €602M — itself benchmarked against a re-cast FY2024 of €660M, which is below the €792M FCF that fell out of the FY2024 cash-flow statement. None of these are arithmetically wrong, but the menu allows management to frame cash generation as anything from a 95% collapse to a modest 9% comparable decline.
CFO has run above net income every year, with an accrual ratio (NI − CFO over average total assets) of -9.9% in FY24 and -2.9% in FY25. That is the conservative direction. The conservatism narrowed sharply in FY25 — primarily because of separation cash costs and the €905M inventory subsidy outflow, both of which hit operating cash flow rather than investing.
Three FCF presentations
The comparable FCF bridge does two things at once: (i) strips €564M of separation costs out of FY2025 to lift it from €38M to €602M, and (ii) re-casts FY2024 downward from €803M to €660M by adding hypothetical TSA depreciation (€38M) and interest costs (€105M) that did not actually occur in 2024. Both adjustments are individually defensible, but together they compress the year-over-year decline from 95% to 9%. The reader should pick one definition and stick with it; we anchor on statement FCF for risk underwriting.
Working capital — Unilever as the swing factor
The €1.1B jump in accounts payable looks like a textbook payables-stretch lifeline, but €818M of it is the inventory accrual owed to Unilever because legal title has not yet passed for inventory still in Unilever's possession across most markets. The remainder is consistent with normal growth in trade payables. Inventory actually fell €47M year over year. Payables-days, on the operational portion, are roughly flat per management — we accept that with the caveat that the bridge between aggregate balance-sheet movements and operational working capital is not directly auditable from the public CF statement, and will need re-verification once the Transitional Period closes.
Metric Hygiene
The non-IFRS framework runs on five definitions investors need to test independently: Organic Sales Growth (OSG), Adjusted EBITDA, Adjusted EBIT, Adjusted EPS, and Comparable Free Cash Flow. The exclusions are individually plausible — separation costs, IT-stack build, hyperinflation under IAS 29, FX translation, Replacement PSP true-up costs — but they aggregate to €656M of EBITDA "adjustments" in FY2025 (about 8.3% of revenue), and the 2026 guidance for adjusting items is essentially flat at €425M–€450M. A non-IFRS framework that delivers €1bn-plus of headline cushion two years in a row deserves to be tested, not accepted.
KPI definition hygiene
The one red item is Adjusted EPS for FY2025 with no comparator: pre-listing, there were no issued shares, so management could not produce an Adjusted EPS series. That removes the most disciplining test (year-over-year adjusted EPS trend) for the first full annual cycle. Even directionally honest CFOs cannot retrofit a clean prior-year adjusted-EPS — but investors should not treat the €0.93 figure as a comparable run-rate until FY2026 actuals land.
What to Underwrite Next
The watch-list is short and concrete. The next three items will determine whether this Watch rating tightens or loosens:
Accounting risk here is a valuation haircut and a position-sizing limiter, not a thesis breaker. The carve-out structure makes GAAP-to-comparable bridges inevitable; the question is whether management uses the bridges to hide or to communicate. So far the disclosure quality is high, the cash mechanics tie back to a single demerger event, and KPMG is fully engaged. We would underwrite this name on GAAP operating profit and statement FCF, apply a modest discount to the EV/Adjusted-EBITDA multiple investors will be tempted to anchor on, and keep position size below normal until the FY2026 SOX 404(b) opinion lands and the Transitional Period unwind becomes legible.